Abstract
Introduction

DNA methylation involves the addition of a methyl group to the number 5 carbon of the cytosine ring in the CpG dinucleotide, by
catalysing the conversion of cytosine into methylcytosine through DNA methyltransferase [1, 2] [3] [4] [5] [6] [7] [8] [9] .
. Cancer cells are characterized by global DNA hypomethylation but gene-specific hypermethylation of promoter-associated CpG islands of tumour suppressor genes (TSGs), resulting in transcriptional repression, and hence serve as an alternative mechanism of gene inactivation. Based on a pathway-specific approach, multiple TSGs across pathways including cell cycle regulation, Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling, WNT signalling and death-associated protein (DAP) kinase-associated intrinsic tumour suppression have been shown to be inactivated by gene hypermethylation in leukaemia, lymphoma and multiple myeloma
MicroRNA (miRNA) is a single-stranded, non-coding RNA molecule of [22] [23] [24] [25] nucleotides, which leads to down-regulation of target protein expression [10] .
miRNAs are involved in carcinogenesis. miRNAs can be either oncogenic (oncomir) when TSGs are targeted, or tumour suppressive (tumour suppressor miRNAs)
when oncogenes are targeted [10, 11] . Little is known about the role of hypermethylation of tumour suppressor miRNAs in haematological cancers.
Recently, hypermethylation of hsa-miR-203 has been reported in chronic myeloid leukaemia (CML) and hepatocellular carcinoma, conferring proliferative advantage in tumour cells [12, 13] . Specifically 
Materials and methods
Patient samples
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from bone marrow samples of ALL, AML, CML and CLL at diagnosis, diagnostic tissues (either lymph node or nasal biopsy in nasal NK-cell lymphoma) in patients with NHL, and cell lines by standard method.
MSP for aberrant gene promoter methylation was performed as previously described [18] . 
Treatment of DNA with bisulphite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with a commercially available kit (EpiTect Bisulphite Kit, QIAGEN, Hilden, Germany). Methylated MSP (M-MSP) primers were forward: 5Ј-GAG TAT TTT CGG TTT AGA CGA GAC-3Ј; reverse: 5Ј-CCT TTT ATA CGA CGC AAC CG-3'. Unmethylated MSP (U-MSP) primers were forward: 5Ј-TTT GAG TAT TTT TGG TTT AGA TGA GAT-3Ј; reverse: 5Ј-AAC ACC TTT TAT
5-Aza-2Ј-deoxycytidine (5-AzadC) treatment
Statistical analysis
and methylation of hsa-miR-34a, -124a and -196b) were studied by Student's t-test and chi-square test (or Fisher's exact test), respectively. OS is measured from the date of diagnosis to the date of last follow-up or death. In CLL, OS of patients with limited Rai stage (stages 0, I and II) were compared to those with advanced stage (stages III and IV). Survival is plotted by the Kaplan-Meier method and compared by the log-rank test. All Pvalues were two sided. In NHL, correlation between hsa-miR-203 methylation with continuous (mean age) and categorical variables (gender, lineage [B, T or NK/T], nodal/extranodal presentation and methylation of hsa-miR34a, -124a and -196b) were studied by Student's t-test and chi-square test (or Fisher's exact test), respectively.
Results
MSP Controls
None of the eight normal control marrows showed aberrant methylation of hsa-miR-203 by MSP (Fig. 1A) (Fig. 2C) . Fig. 3A) , with re-expression of mature miR-203 as shown by Taqman stem-loop RT-qPCR (Fig. 3B) .
Leukaemia and lymphoma cell lines The profile of methylation of hsa-miR-203 of leukaemia and lymphoma cell lines was shown in Fig. 1B. SU-DHL-6, SU-DHL-16, JEKO-1, MINO, HL-60 and SKNO-1 were homozygously methylated for hsa-miR-203.
Primary samples at diagnosis Direct sequencing of the M-MSP products from the methylated primary samples showed the expected nucleotide changes after bisulphite treatment, therefore confirming complete bisulphite conversion and specificity of MSP (Fig. 2A). hsa-miR-203 hypermethylation was not detected in any of the CML. On the other hand, hsa-miR-203 methylation was preferentially found in NHL patients with methylation occurring in 1 (5%) ALL, 2 (10%)
AML
5-AzadC treatment of lymphoma cells
JEKO-1 cells were completely methylated for hsa-miR-203. Upon 5-AzadC demethylation treatment, hsa-miR-203 U-MSP signal emerged on day 3 (
Effect of miR-203 overexpression in lymphoma cells
Upon transfection of mature miR-203 mimic which led to overexpression mature miR-203 (Fig. 4A) , JEKO-1 showed 20% reduction in cell proliferation as compared with the negative control at 24th hr by MTT assay (Fig. 4B) , and 2-fold increase of dead cells as measured by trypan blue exclusion assay (Fig. 4C) 
NK/T cell lymphoma is an Epstein-Barr virus-associated, aggressive extranodal lymphoma more frequently encountered in
Asia, and Central and South America [22] . As yet, only few TSGs have been shown to be hypermethylated in NK/T cell lymphoma including p73, CDKN2A, CDKN2B, hMLH1 and RAR␤ [23] . On the other hand, as yet, miR-34a was the only miRNA reported to be hypermethylated in NK/T cell lymphoma [24] . Therefore 
